Implementation of Article 20 of the World Health Organization Framework Convention on Tobacco Control

Dhirendra Narain Sinha¹, Amit Kumar², Ruchika Gupta³, Harleen Kaur Gulati⁴, Sanjay Gupta¹ & Ravi Mehrotra⁴

¹School of Preventive Oncology, Patna, ²Data Management Laboratory, ³Division of Cytopathology & ⁴WHO FCTC Global Knowledge Hub for Smokeless Tobacco, ICMR-National Institute of Cancer Prevention & Research, Noida, India

Received February 9, 2018

Background & objectives: Article 20 of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) deals with surveillance and research on all tobacco products including smokeless tobacco (SLT). Here we describe the availability of indicators related to SLT among 180 Parties to the convention (countries ratifying the WHO FCTC are referred as Parties to the Convention).

Methods: Data on SLT use among adults and adolescents and SLT-related economic and health indicators among Parties were obtained through rigorous literature search. Data analysis for high-burden parties was done using SPSS.

Results: Nearly 92 per cent (166) of the Parties reported SLT use prevalence among adults or adolescents at national or subnational level, of these nearly one-fifth of the Parties (20.5%) were high-burden Parties. Comparable SLT tax incidence rate was available for 19.4 per cent (n=35) Parties, and SLT attributable morbidity and mortality risks of major diseases were available for only five per cent (n=10) of Parties.

Interpretation & conclusions: SLT use is a global epidemic widespread among Parties to the Convention. There are a data gap and dearth of research on SLT-related issues. Parties need to monitor SLT use and related health and economic indicators regularly at periodic intervals.

Key words Economics - health - prevalence - smokeless tobacco - WHO FCTC

Member countries that have ratified World Health Organization Framework Convention on Tobacco Control (WHO FCTC) are called ‘Parties to the Convention’. There are 181 Parties to the Convention including 180 countries and European Union¹. Article 20 of the WHO FCTC deals with research, surveillance and exchange of information on tobacco products including smokeless tobacco (SLT). In the context of SLT control, the Article mandates to carry out appropriate scientific national research and the establishment of surveillance mechanisms. It also mandates undertaking of programmes that address the magnitude, patterns, determinants, related social, economic and health indicators and consequences of SLT consumption. This Article also includes information regarding how to facilitate the cooperative exchange of SLT control-related information and provision of support, with special focus on developing Parties².
Parties to the Convention report progress on individual Articles including Article 20. Last two global progress reports on implementation of WHO FCTC (2014 and 2016) reported on SLT use prevalence indicators. According to the FCTC global implementation report 2016, about 47 per cent of the reporting Parties (n=132) provided data on the prevalence of SLT use among adults. Around 12 per cent of the reporting Parties were identified as having at least two comparable datasets across all reporting cycles for adult SLT use. Last global progress report of 2016 presented SLT use indicator among 132 of all Parties to the Convention. This study was conducted to document progress of Article 20 on SLT use prevalence and its related indicators such as health and economic indicators among all Parties to the Convention.

Material & Methods

All 180 Parties to the Convention were included in the analysis. The European Union as a Party was excluded (as it represents a group of countries that are already included in 180 Parties).

Data sources:

(i) Tobacco use prevalence among adults and adolescents was obtained from the health survey reports of individual countries, from Global Tobacco Surveillance System - Global Adult Tobacco Survey, Global Youth Tobacco Survey, Demographic Health Survey, WHO STEPSwise NCD Risk Factors survey and Global School Health Survey reports or published data in indexed journals and secondary analysis from the original sources. We included national and subnational data from all Parties, provided that they met indicator definition (Table I). National data of a country were included if the sample was designed to estimate their national prevalence either by combining their regional estimates or rough national estimates. Subnational estimates were defined if this sample was drawn from one such geographic region of the country.

Table I. Definitions of the indicators evaluated in this study

| Prevalence | SLT use among adults: Current use of SLT among adults (aged 15+ yr) reported during 2003 and 2017 |
| SLT use among adults: Current use of SLT among adults aged 15+ yr reported during 2013-2017 |
| High SLT burden Parties (Adults): Parties having SLT use prevalence ≥10% either among male or female adults |
| SLT use among adolescents: Current use of SLT among adolescents aged 13-15 yr reported during 2003-2017 |
| Recent data on SLT use among adolescents: Current use of SLT among adolescents aged 13-15 yr reported during 2013-2017 |
| High SLT burden Parties (adolescents): Parties having SLT use prevalence ≥10% either among male or female adolescents |
| Overall high burden countries were defined as those with a prevalence of SLT use more than 10% either among male or female adults or either among male or female adolescents |
| Overall SLT use prevalence: Parties having SLT use prevalence either among adults or adolescents either at national or subnational level |

| Health effects | Risk of oral cancer and other cancers among adult SLT users aged 30+ or 35+ yr reported during 2003-2017 |
| Risk of cardiovascular diseases among adult SLT users aged 30+ yr reported during 2003-2017 |
| Risk of adverse reproductive outcomes in female adult SLT users reported during 2003-2017 |
| All-cause mortality among adult SLT users aged 30+ yr reported during 2003-2017 |
| Cancer-related mortality among adult SLT users aged 30+ yr reported during 2003-2017 |
| Mortality due to oral/oropharyngeal/upper aerodigestive tract cancers among adult SLT users aged 30+ yr reported during 2003-2017 |
| Cardiovascular-related mortality among adult SLT users aged 30+ yr reported during 2003-2017 |

| Economic effect | Data on SLT taxation: Parties having comparable price and tax incidence rates for SLT at one point of time during 2003-2017 |
| Recent data on SLT taxation: Parties having comparable SLT price and tax incidence rates during 2013-2017 |
| Parties having comparable SLT price and tax incidence rates for more than one point of time |
| Parties having SLT attributable health cost study during 2003-2017 |

SLT, smokeless tobacco

Source: Refs 5-39.
(ii) Data on health impacts of SLT use (morbidity and mortality) were obtained from published cohort and case-control studies16-35.

(iii) Data on economics of SLT control were obtained from two sources: (a) Comparable tax data on SLT products obtained from the WHO Global Tobacco Epidemic Reports of 2015 and 20178,9. Data reported by countries where methodology was not provided, were excluded from this study; (b) Costs incurred attributable to SLT use and incomes from SLT were collected from country reports commissioned by Governments or WHO16-39.

Results & Discussion

Parties having prevalence data at either national or subnational level among adults or adolescents: Nearly 92 per cent (n=165) of the Parties had SLT use information for adults or adolescents either at national or subnational levels.

| Table II. Number and percentage of Parties having data on prevalence, health and economic indicators of smokeless tobacco (SLT) use |
|-----|-----|-----|
| Indicator                                      | Number of countries | Per cent of Parties |
| SLT use prevalence                             |                   |                   |
| SLT use among adults                           | 138               | 76.6              |
| Recent SLT use among adults                    | 60                | 33.3              |
| High SLT burden Parties (adults)               | 26                | 14.4              |
| SLT use among adolescent                       | 133               | 73.9              |
| Recent SLT use among adolescent                | 80                | 44.4              |
| High SLT burden Parties (adolescents)          | 21                | 11.6              |
| Overall high SLT burden Parties (adults and adolescents combined) | 37                | 20.5              |
| Overall SLT use                                | 166               | 92                |
| SLT-attributable major diseases risk factors   |                   |                   |
| Risk estimate of oral cancer                   | 6                 | 3.3               |
| Risk estimate of other cancers                 | 5                 | 2.7               |
| Risk estimate of cardiovascular diseases        | 6                 | 3.3               |
| Risk estimate of adverse reproductive outcomes  | 4                 | 2.7               |
| All-cause mortality estimate                   | 3                 | 1.6               |
| Cancer-related mortality estimate              | 3                 | 1.6               |
| Mortality estimate due aerodigestive tract cancers | 1               | 0.5               |
| Cardiovascular-related mortality estimate       | 3                 | 1.6               |
| Economic indicators                            |                   |                   |
| Comparable price and tax incidence rates for SLT at one point of time and those all are recent | 35                | 19.4              |
| Comparable price and tax incidence rates for SLT for more than one point of time | 8                | 4.4               |
| Health cost studies attributable to SLT use    | 2                 | 1.1               |
Parties having SLT use data among adolescents: Nearly 67.7 per cent (n=122) of the Parties reported SLT use among adolescents at national level. Angola, Brazil, Burkina Faso, Central African Republic, Democratic Republic of the Congo, Gambia, Liberia, Nigeria, Sierra Leone, United Republic of Tanzania and Zambia provided subnational data (6%) (Table II). Nearly 44.4 per cent (n=80) of the Parties had recent data (after 2013) on adolescent SLT prevalence (Table II), mostly from HIC and UMIC). Bhutan, Botswana, Congo, Croatia, Dominica, Iceland, India, Lesotho, Malaysia, Marshall Islands, Micronesia (Federated States of), Mongolia, Palau, Papua New Guinea, Vanuatu were high-burden Parties having prevalence ≥10 per cent (either male or female adolescents) and accounted for 11.6 per cent of the Parties (Tables II & III).

Overall SLT use prevalence: Overall, 92 per cent of the Parties (n=166) had SLT use prevalence among adults or adolescents either at national or subnational level (Table II). Thirty seven Parties (20.5%) were high-burden Parties where the prevalence of SLT use was 10 per cent or higher among adolescents or adults (Tables II & III).

Smokeless tobacco-related health indicators: Only 10 Parties (Bangladesh, India, Iran, Norway, Pakistan, Sweden, Sudan, Saudi Arabia, South Africa and Yemen) had data on risks known for major diseases attributable to SLT use (Table II). Major diseases included were oral cancers, other cancers, cardiovascular diseases and adverse reproductive outcomes. Oral cancer risk among adult SLT users was available for six Parties only (Sweden, India, Pakistan, Bangladesh, Sudan and Saudi Arabia). Risk estimate of other cancers among adult SLT users was available for five Parties only (Sweden, India, Pakistan, Bangladesh and Yemen). Risk estimate of cardiovascular diseases among SLT users was available for six Parties only (Sweden, Norway, India, Bangladesh, Pakistan and Iran). Risk estimate of adverse reproductive outcomes among female adult SLT users was available for four Parties only (Sweden, India, Bangladesh and South Africa). All-cause mortality among adult SLT users was available for three Parties only (Sweden, India and Bangladesh). Cancer mortality among SLT users was available for three Parties only (Sweden, India and Bangladesh). Mortality estimate due to oral/oropharyngeal/upper aerodigestive tract cancers among SLT users was available for one Party only (India). Cardiovascular mortality estimate among adult SLT users was available for three Parties only (Sweden, India and Bangladesh).

Economic indicators related to SLT use: Thirty five Parties had comparable price and tax incidence rates for SLT at one point of time and all are recent (Table II). Eight Parties have comparable price and tax incidence rates for SLT for more than one point of time. India conducted health cost studies attributable to SLT for two rounds and Bangladesh for one round during 2004-2006.

Parties to the Convention are obligated to carry out surveillance and research on SLT use and related
indicators. This study showed that SLT use was widely prevalent among 92 per cent of Parties. Prior studies have also indicated that SLT use is a global epidemic\(^4,^9\). There is now ample evidence from studies\(^5-^30\), including the present one, that SLT burden is mainly concentrated in developing world. Data gap on evidence collection on SLT-related indicators can partly be attributed to inadequate resources and capacities for surveillance and research in low-income countries as well as low- and middle-income countries\(^5\). There was lack of data for SLT use in eight per cent of the Parties. There could be different reasons for this data gap such as ignorance and lack of commitment for SLT control among many parties. Many data sources were not in public domain and many reports were in regional languages. Another notable finding was non-availability of recent data from many Parties.

Robust research, surveillance systems and monitoring programmes are critical to the success of addressing the global SLT epidemic. Our study had certain limitations. The data analysed in this study pertained only to the available data in English language literature and thus could be underrepresented. Comparability of data was also a major issue.

In conclusion, Parties (especially in SEAR and in low- and low-middle-income countries) should establish sustainable resources for periodic monitoring of the magnitude, patterns, determinants and related social, economic and health consequences of SLT use. Parties should contact and communicate with international partners to strengthen resources and build capacity for monitoring and research on specific tobacco control issues in their respective countries.

Financial support & sponsorship: None.

Conflicts of Interest: None.

References

1. United Nations Treaty Collection, World Health Organization. Parties to the WHO framework convention on tobacco control. 2012. Available from: https://treaties.un.org/pages/viewdetails.aspx?src=treaty&mtdsg_no=ix-4&chapter =9&clang_=en, accessed on January 26, 2018.

2. World Health Organization. WHO framework convention on tobacco control. Geneva, Switzerland: World Health Organization; 2003. Available from: http://www.who.int/fctc/text_download/en/, accessed on August 9, 2017.

3. WHO FCTC. Global progress report on implementation of the WHO framework convention on tobacco control. Geneva: WHO; 2014. Available from: http://www.who.int/fctc/reporting/2014globalprogressreport.pdf?ua=1, accessed on January 28, 2018.

4. WHO FCTC. Global progress report on implementation of the WHO framework convention on tobacco control. Geneva: World Health Organization; 2016. Available from: http://www.who.int/fctc/reporting/2016_global_progress_report.pdf?ua=1, accessed on January 26, 2018.

5. Sinha DN, Gupta PC, Kumar A, Bhartiya D, Agarwal N, Sharma S, et al. The poorest of poor suffer the greatest burden from smokeless tobacco use: A study from 140 countries. Nicotine Tob Res 2017 Dec 22. doi: 10.1093/ntr/ntx276.

6. Sinha DN, Kumar A, Bhartiya D, Sharma S, Gupta PC, Singh H, et al. Smokeless tobacco use among adolescents in global perspective. Nicotine Tob Res 2017; 19: 1395-6.

7. National Cancer Institute and Centers for Disease Control and Prevention. Smokeless tobacco and public health: A global perspective. NIH Publication No 14-7983. Bethesda, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Institutes of Health, National Cancer Institute; 2014. Available from: https://www.cancercontrol.cancer.gov/brp/tcrb/global-perspective/SmokelessTobaccoAndPublicHealth.pdf, accessed on December 12, 2017.

8. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2015: Raising taxes on tobacco. Available from: http://apps.who.int/iris/bitstream/10665/178574/1/9789240694606_eng.pdf?ua=1&ua=1, accessed on January 10, 2018.

9. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017: Monitoring tobacco use and prevention policies. Available from: http://apps.who.int/iris/bitstream/10665/255874/1/9789241512824-eng.pdf?ua=1&ua=1, accessed on January 10, 2018.

10. Sreeramareddy CT, Pradhan PM. Prevalence and social determinants of smoking in 15 countries from North Africa, central and Western Asia, Latin America and Caribbean: Secondary data analyses of demographic and health surveys. PLoS One 2015; 10 : e0130104.

11. Sreeramareddy CT, Pradhan PM, Sin S. Prevalence, distribution, and social determinants of tobacco use in 30 sub-Saharan African countries. BMC Med 2014; 12 : 243.

12. Sreeramareddy CT, Pradhan PM, Mir IA, Sin S. Smoking and smokeless tobacco use in nine South and Southeast Asian countries: Prevalence estimates and social determinants from demographic and health surveys. Popul Health Metr 2014; 12 : 22.

13. Global Tobacco Surveillance System Data, Centers for Disease Control and Prevention, Atlanta. Available from: https://www.cdc.gov/tobacco/global/gtss/gtssdata/index.html, accessed on December 10, 2017.

14. Riley L, Guthold R, Cowan M, Savin S, Bhatti L, Armstrong T, et al. The World Health Organization STEPwise approach to noncommunicable disease risk-factor surveillance: Methods, challenges, and opportunities. Am J Public Health 2016; 106 : 74-8.

15. U.S. Department of Health and Human Services. Demographic and health surveys. Rockville, MD: U.S. Department of Health and Human Services; 1989. Available from: https://www.dhsprogram.com, accessed on December 23, 2017.
16. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. *Lancet Oncol* 2008; 9: 667-75.

17. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: Systematic review with meta-analysis. *BMJ* 2009; 339 : b3060.

18. Vidyasagar A L, Siddiqui K, Kanaan M. Use of smokeless tobacco and risk of cardiovascular disease: A systematic review and meta-analysis. *Eur J Prev Cardiol* 2016; 23 : 1970-81.

19. Sinha DN, Suliankatchi RA, Gupta PC, Thamarangsi T, Agarwal N, Parascandola M, et al. Global burden of all-cause and cause-specific mortality due to smokeless tobacco use: Systematic review and meta-analysis. *Tob Control* 2018; 27 : 35-42.

20. Siddiqui K, Shah S, Abbas SM, Vidyasagar A, Jawad M, Dogar O, et al. Global burden of disease due to smokeless tobacco consumption in adults: Analysis of data from 113 countries. *BMC Med* 2015; 13 : 194.

21. Sinha DN, Abdulkader RS, Gupta PC. Smokeless tobacco-associated cancers: A systematic review and meta-analysis of Indian studies. *Int J Cancer* 2016; 138 : 1368-79.

22. Idris AM, Ahmed HM, Malik MO. Toombak dipping and cancer of the oral cavity in the Sudan: A case-control study. *Int J Cancer* 1995; 63 : 477-80.

23. Luo J, Ye W, Zendehdel K, Adami J, Adami HO, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A retrospective cohort study. *Lancet* 2007; 369 : 2015-20.

24. Gajalakshmi V, Kanimozhi V. Tobacco chewing and adult mortality: A case-control analysis of 22,000 cases and 429,000 controls, never smoking tobacco and never drinking alcohol, in South India. *Asian Pac J Cancer Prev* 2015; 16 : 1201-6.

25. Bolinder G, de Faire U. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers and nontobacco users. *Am J Hypertens* 1998; 11 : 1153-63.

26. Hergens MP, Lambe M, Pershagen G, Ye W. Risk of hypertension amongst Swedish male snuff users: A prospective study. *J Intern Med* 2008; 264 : 187-94.

27. Ayo-Yusuf OA, Omole OB. Snuff use and risk for hypertension among black South African women. *South Afr Fam Pract* 2008; 50 : 64.

28. Sunanda P, Panda B, Dash C, Ray PK, Padhy RN, Routray P, et al. Prevalence of abnormal spermatozoa in tobacco chewing sub-fertile males. *J Hum Reprod Sci* 2014; 7 : 136-42.

29. England LJ, Kim SY, Tomar SL, Ray CS, Gupta PC, Eissengr T, et al. Non-cigarette tobacco use among women and adverse pregnancy outcomes. *Acta Obstet Gynecol Scand* 2010; 89 : 454-64.

30. Wikström AK, Cnattingius S, Galanti MR, Kieler H, Stephanson O. Effect of Swedish snuff (snus) on preterm birth. *BJOG* 2010; 117 : 1005-10.

31. Baba S, Wikström AK, Stephanson O, Cnattingius S. Influence of snuff and smoking habits in early pregnancy on risks for stillbirth and early neonatal mortality. *Nicotine Tob Res* 2014; 16 : 78-83.

32. Baba S, Wikström AK, Stephanson O, Cnattingius S. Changes in snuff and smoking habits in Swedish pregnant women and risk for small for gestational age births. *BJOG* 2013; 120 : 456-62.

33. Gupta PC, Subramoney S. Smokeless tobacco use and risk of stillbirth: A cohort study in Mumbai, India. *Epidemiology* 2006; 17 : 47-51.

34. Inamdar AS, Croucher RE, Chokhandre MK, Mashyakhy MH, Marinho VC. Maternal smokeless tobacco use in pregnancy and adverse health outcomes in newborns: A systematic review. *Nicotine Tob Res* 2015; 17 : 1058-66.

35. Suliankatchi RA, Sinha DN. The human cost of tobacco consumption in newborns. *J Obstet Gynaecol India* 2016; 66 : 161-6.

36. Rath G K. Conversation with Dr. G. K. Rath. [Interviewed by Sapna Gupta]. *J Cancer Res Ther* 2011; 7 : 235-6.

37. National Informatics Centre. *Economic burden of tobacco related diseases in India, executive summary*. New Delhi: Ministry of Health and Family Welfare; 2017. Available from: http://www.searo.who.int/india/topics/tobacco/economic_burden_of_tobacco_related_diseases_in_india_executive_summary.pdf, accessed on August 9, 2017.

38. World Health Organization. *Impact of tobacco related illnesses in Bangladesh. Bangladesh health cost study*. New Delhi: WHO Regional Office for South-East Asia; 2007. Available from: http://www.searo.who.int/tobacco/documents/2007-pub1.pdf?ua=1, accessed on August 9, 2017.

39. Mehrotra R, Sinha DN, Sziglgyi T, editors. Global smokeless tobacco control policies and their implementation, 1st ed. Noida: ICMR - National Institute of Cancer Prevention and Research; 2017.

For correspondence: Dr Dhirendra Narain Sinha, School of Preventive Oncology, A/27, Anand Puri, West Boring Canal Road, Patna 800 001, Bihar, India e-mail: dhirendrasinhaind@gmail.com